Terms: = Prostate cancer AND NTRK1, ENSG00000198400, 4914, P04629, TRK1, MTC, DKFZp781I14186, p140-TrkA, TRKA, TRK AND Treatment
27 results:
1. Oncocytoid Salivary Tumors: Differential Diagnosis and Utility of Newly Described Immunohistochemistry.
Katabi N
Head Neck Pathol; 2024 Mar; 18(1):20. PubMed ID: 38502259
[TBL] [Abstract] [Full Text] [Related]
2. trka promotes MDM2-mediated AGPS ubiquitination and degradation to trigger prostate cancer progression.
Zhang Y; Huang Z; Li K; Xie G; Feng Y; Wang Z; Li N; Liu R; Ding Y; Wang J; Yang J; Jia Z
J Exp Clin Cancer Res; 2024 Jan; 43(1):16. PubMed ID: 38200609
[TBL] [Abstract] [Full Text] [Related]
3. FBXO22 Mediates the NGF/trka Signaling Pathway in Bone Metastases in prostate cancer.
Zhang Y; Li W; Guo S; Wu Z; Zhang L; Liu Y; Li X; Guo X; Cao J; Yang C; Wang Z
Am J Pathol; 2023 Sep; 193(9):1248-1266. PubMed ID: 37301536
[TBL] [Abstract] [Full Text] [Related]
4. Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?
Pereira-Salgado A; Anton A; Franchini F; Mahar RK; Kwan EM; Wong S; Shapiro J; Weickhardt A; Azad AA; Spain L; Gunjur A; Torres J; Parente P; Parnis F; Goh J; Steer C; Brown S; Gibbs P; Tran B; IJzerman M
Expert Rev Pharmacoecon Outcomes Res; 2023 Feb; 23(2):231-239. PubMed ID: 36541133
[TBL] [Abstract] [Full Text] [Related]
5. Microwave focal therapy of prostate cancer: a non-clinical study and exploratory clinical trial.
Boku H; Kaneko M; Yamada Y; Morinaga Y; Konishi E; Uno A; Ito-Ihara T; Yamada A; Horiguchi G; Teramukai S; Fujihara A; Shiraishi T; Yamada T; Ueda T; Matsugasumi T; Ohashi M; Horiuchi D; Inoue Y; Ukimura O
BJU Int; 2022 Dec; 130(6):776-785. PubMed ID: 35434902
[TBL] [Abstract] [Full Text] [Related]
6. South African guidelines for receptor radioligand therapy (RLT) with Lu-177-PSMA in prostate cancer.
Vorster M; Warwick J; Lawal IO; Du Toit P; Vangu M; Nyakale NE; Steyn R; Gutta AA; Hart G; Mutambirwa S; Ellmann A; Sathekge MM
S Afr J Surg; 2019 Dec; 57(4):45-51. PubMed ID: 31773936
[TBL] [Abstract] [Full Text] [Related]
7. A novel PTPRZ1-ETV1 fusion in gliomas.
Matjašič A; Zupan A; Boštjančič E; Pižem J; Popović M; Kolenc D
Brain Pathol; 2020 Mar; 30(2):226-234. PubMed ID: 31381204
[TBL] [Abstract] [Full Text] [Related]
8. Incidence of surgical interventions for metastatic bone disease in the extremities: a population-based cohort study.
Skovlund Sørensen M; Hindsø K; Frederik Horstmann P; Troelsen A; Dalsgaard S; Fog T; Zimnicki T; Mørk Petersen M
Acta Oncol; 2019 Apr; 58(4):456-462. PubMed ID: 30632859
[TBL] [Abstract] [Full Text] [Related]
9. [Cabozantinib: Mechanism of action, efficacy and indications].
Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S
Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875
[TBL] [Abstract] [Full Text] [Related]
10. Sensitivity Profiles of Human prostate cancer Cell Lines to an 80 Kinase Inhibitor Panel.
Burke AJ; Ali H; O'Connell E; Sullivan FJ; Glynn SA
Anticancer Res; 2016 Feb; 36(2):633-41. PubMed ID: 26851018
[TBL] [Abstract] [Full Text] [Related]
11. Cabozantinib in Thyroid cancer.
Fallahi P; Ferrari SM; Di Bari F; Materazzi G; Benvenga S; Miccoli P; Antonelli A
Recent Pat Anticancer Drug Discov; 2015; 10(3):259-69. PubMed ID: 26152149
[TBL] [Abstract] [Full Text] [Related]
12. A novel multiple tyrosine-kinase targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple solid tumors: cabozantinib.
Roy S; Narang BK; Rastogi SK; Rawal RK
Anticancer Agents Med Chem; 2015; 15(1):37-47. PubMed ID: 25181996
[TBL] [Abstract] [Full Text] [Related]
13. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.
Grüllich C
Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794
[TBL] [Abstract] [Full Text] [Related]
14. Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis.
Palmieri C; Fullarton JR; Brown J
Clin Cancer Res; 2013 Dec; 19(24):6863-72. PubMed ID: 24166910
[TBL] [Abstract] [Full Text] [Related]
15. Vandetanib: first global approval.
Commander H; Whiteside G; Perry C
Drugs; 2011 Jul; 71(10):1355-65. PubMed ID: 21770481
[TBL] [Abstract] [Full Text] [Related]
16. Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.
Collins C; Carducci MA; Eisenberger MA; Isaacs JT; Partin AW; Pili R; Sinibaldi VJ; Walczak JS; Denmeade SR
Cancer Biol Ther; 2007 Sep; 6(9):1360-7. PubMed ID: 17786033
[TBL] [Abstract] [Full Text] [Related]
17. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.
Festuccia C; Gravina GL; Millimaggi D; Muzi P; Speca S; Ricevuto E; Vicentini C; Bologna M
Oncol Rep; 2007 Aug; 18(2):503-11. PubMed ID: 17611677
[TBL] [Abstract] [Full Text] [Related]
18. In vitro and in vivo effects of bicalutamide on the expression of trka and P75 neurotrophin receptors in prostate carcinoma.
Festuccia C; Gravina GL; Muzi P; Pomante R; Ventura L; Ricevuto E; Vicentini C; Bologna M
Prostate; 2007 Sep; 67(12):1255-64. PubMed ID: 17596848
[TBL] [Abstract] [Full Text] [Related]
19. Tyrosine kinase inhibitor CEP-701 blocks the ntrk1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.
Festuccia C; Muzi P; Gravina GL; Millimaggi D; Speca S; Dolo V; Ricevuto E; Vicentini C; Bologna M
Int J Oncol; 2007 Jan; 30(1):193-200. PubMed ID: 17143529
[TBL] [Abstract] [Full Text] [Related]
20. The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice.
Miknyoczki SJ; Wan W; Chang H; Dobrzanski P; Ruggeri BA; Dionne CA; Buchkovich K
Clin Cancer Res; 2002 Jun; 8(6):1924-31. PubMed ID: 12060637
[TBL] [Abstract] [Full Text] [Related]
[Next]
